Moderators:

• Diana English, MBBS, Stanford University School of Medicine, Stanford, CA
• Rahel Ghebre, MD, University of Minnesota, Minneapolis, MN

Description: Featured posters represent the highest ranked among all poster submissions. During this session, featured poster presenters will each present their abstract in 3 minute talks.

Location: Hawaii Convention Center 313AB

ABSTRACT 42
Factors to explain racial disparity in survival for women with uterine cancer: Further investigations by histologic subtype

C.L. Presti1, C. Tian2, K.E. Oliver3, N.W. Bateman2,4, T.P. Conrads2,4,5, C.A. Hamilton1,2,4,5, Y. Casablanca2,4, G.L. Maxwell1,2,4,5 and K.M. Darcy2,4
1Inova Fairfax Hospital, Falls Church, VA, USA, 2Gynecologic Cancer Center of Excellence, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA, 3Women’s Health Department, Naval Medical Center, Portsmouth, VA, USA, 4John P Murtha Cancer Center, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA, 5Inova Schar Cancer Institute, Inova Center for Personalized Health, Falls Church, VA, USA

ABSTRACT 43
Utilizing the health leads screening toolkit: A quality improvement initiative to detect and address essential and social resource needs in gynecologic oncology clinic patients

A.L. Beavis1, A. Sanneh2, R.L. Stone3, M.R. Vitale4, K. Levinson1, A. Nickles Fader1 and S. Wethington2
1Johns Hopkins Hospital, Baltimore, MD, USA, 2Johns Hopkins School of Medicine, Baltimore, MD, USA, 3Johns Hopkins Hospital, The Kelly Gynecologic Oncology Service, Baltimore, MD, USA, 4Johns Hopkins University, Baltimore, MD, USA

ABSTRACT 44
An economic analysis: Examining the cost-effectiveness of bevacizumab and olaparib as upfront maintenance treatment of advanced ovarian cancer

J.E. Wolford1, S.Y. Liang2, K.S. Tewari3, R.N. Eskander4, D.S. Kapp5, A.K. Mann2 and J.K. Chan6
1UC Irvine Medical Center, Orange, CA, USA, 2Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA, 3University of California Irvine Medical Center, Orange, CA, USA, 4UCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, 5Stanford University School of Medicine, Stanford, CA, USA, 6California Pacific Medical Center, San Francisco, CA, USA

ABSTRACT 45
Patient decision making regarding maintenance therapy for ovarian cancer: A qualitative exploration

L.A. Meyer, C.C.L. Sun, K. Savelieva, V. Leal, L. Crocker, E. Molina, S.N. Westin, R.L. Coleman, R.J. Volk and L.M. Lowenstein
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

ABSTRACT 46
Impact of surgical approach on survival outcomes in women undergoing radical hysterectomy for cervical cancer: A population-based cohort study

M.C. Cusimano1, N.N. Baxter1,2, L.T. Gien1,2,3, R. Moineddin2, N. Liu2, F. Dossa1, H. Raziee4, K.A. Willows1 and S.E. Ferguson1,5
1University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Sunnybrook Odette Cancer Center, Toronto, ON, Canada, 4BC Cancer Agency - Fraser Valley Centre, Surrey, BC, Canada, 5Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

ABSTRACT 47
Multicenter study of minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes

B. Brandt1, V. Sioulas1, K. LaVigne1, M.S. Shahin2, S.F. Bruce2, D. Black3, M. Gandhi3, J.M. Scalici4, N.L. Jones4, R. Paladugu4, J. Brown5, M.D. Levine5, R.W. Naumann6, A. Mendivil7, B. Goldstein7, P.C. Lim8, E. Kang8, L.A. Cantrell9, M.W. Sullivan10, N.R. Abu-Rustum1 and M.M. Leitao Jr.1
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2Abington Memorial Hospital, Abington, PA, USA, 3Louisiana State University Health Science Center, Shreveport, LA, USA, 4Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA, 5Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, 6Levine Cancer Institute, Charlotte, NC, USA, 7Gynecologic Oncology Associates, Newport Beach, CA, USA, 8Center of Hope, Reno, NV, USA, 9University of Virginia, Charlottesville, VA, USA, 10University of Virginia Health System,
Charlottesville, VA, USA

ABSTRACT 48
The impact of surgeon learning curve and hospital volume on the survival of stage IB cervical cancer patients after minimally invasive surgery

S. Chow1, C.I. Liao2, D.S. Kapp3, A.K. Mann4 and J.K. Chan5
1Kaiser Permanente Santa Clara, Santa Clara, CA, USA, 2Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, 3Stanford University School of Medicine, Stanford, CA, USA, 4Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA, 5California Pacific Medical Center, San Francisco, CA, USA

ABSTRACT 49
Patterns of recurrence and survival of node-positive cervical cancer after open versus laparoscopic radical surgery

Y.J. Young Jae1, D.Y. Kim2, S.W. Lee1, D.S. Suh1, Y.M. Kim1 and J.H. Nam1
1University of Ulsan College of Medicine, ASAN Medical Center, Seoul, South Korea, 2ASAN Medical Center, Seoul, South Korea

ABSTRACT 50
Surgical site infection rates in vulvar surgery: Evidence-based approach to optimal wound classification

I. Mert, B.A. Cliby, K.A. Bews, E.B. Habermann and S.C. Dowdy
Mayo Clinic, Rochester, MN, USA

ABSTRACT 51
Outcomes associated with chemoradiation versus radiation alone in squamous cell carcinoma of the vulva

T. Castellano1, D. Brinkman2, K. Ding3 and C.C. Gunderson1
1The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2The University of Oklahoma, Norman, OK, USA, 3The University of Oklahoma, Oklahoma City, OK, USA

ABSTRACT 52
Oncological results and recurrent risk factors following abdominal radical trachelectomy (ART): An updated series of 333 patients

X. Wu and X. Li
Fudan University Shanghai Cancer Center, Shanghai, China

ABSTRACT 53
Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancer

G. Altwerger1, C. Han1, B. Zeybek1, K. Haines1, G.M. Gressel2, G.S. Huang1, B. Litkouhi1, M. Azodi1,3, D.A. Silasi1, A.D. Santin1, P.E. Schwartz1 and E.S. Ratner1
1Yale University School of Medicine, New Haven, CT, USA, 2Montefiore Medical Center, Bronx, NY, USA, 3Smilow Cancer Hospital at Yale and Yale University, New Haven, CT, USA

ABSTRACT 54
Does the fallopian tube influence the metastatic potential of uterine serous and clear cell carcinoma?

J.H. Jang1, A. Albert2 and J.S. Kwon1
1University of British Columbia, Vancouver, BC, Canada, 2Women’s Health Research Institute, Vancouver, BC, Canada

ABSTRACT 55
Rate of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer

J.R. Salinaro1, R.B. Boccaccio2, J.A. Ehrisman3, L.J. Havrilesky3, A.A. Secord4, K.N. Moore2 and B.A. Davidson3
1Duke University School of Medicine, Durham, NC, USA, 2The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 3Duke University Medical Center, Durham, NC, USA, 4Duke Cancer Institute, Durham, NC, USA

ABSTRACT 56
Assessing the social determinants of health: A pilot performance improvement project

N.C. Nyakudarika1, E. Pineda2, R. Machicado3, M. Kreutzer Joo3, J.G. Cohen1, S. Memarzadeh1, C.H. Holschneider2 and A.K. Sinno1
1University of California, Los Angeles, Los Angeles, CA, USA, 2Olive View-UCLA Medical Center, Sylmar, CA, USA, 3Olive View-UCLA Medical Center, Los Angeles, CA, USA

ABSTRACT 57
The M.B.E.C. study: Menopause, bleeding, and endometrial cancer among black women: A community-engaged qualitative analysis

K.M. Doll1, B. Hempstead2, J. Alson1 and E. Kellogg1
1University of Washington Medical Center, Seattle, WA, USA, 2Cierra Sisters, Seattle, WA, USA

ABSTRACT 58
The first nationwide Japanese multicenter study: Characterizing the cross-sectional approach to ovarian cancer genetic testing of BRCA (CHARLOTTE)

K. Yoshihara1, T. Enomoto1, D. Aoki2, Y. Watanabe3, J. Kigawa4, N. Takeshima5, K. Fujikawa6, K. Hattori6, H. Tsuda7 and T. Sugiyama8
1Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Tohoku Medical and Pharmaceutical University, Sendai, Japan, 4Matsue City Hospital, Matsue, Japan, 5Cancer Institute Hospital, Tokyo, Japan, 6AstraZeneca K.K., Osaka, Japan, 7National Defense Medical College, Tokorozawa, Japan, 8Takagi Hospital, Okawa, Japan